We have recently examined our zygomatic implant data within Merseyside. Our overall survival rate is 93% across all our high priority groups including

• Head & Neck Cancer
• Cleft palate cases
• Severe maxillary atrophy

Our cancer cases made up 70% of our sample and include at least 100 fixtures placed in oncology patients. Of these cases, 40% used the remote anchorage concept and 45% were irradiated either before or after placement. The overall survival in our oncology group was 90% which is extremely encouraging in such a complex group of patients.